STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review

Sanofi has asked the FDA to pull its type 1 diabetes drug, teplizumab, out of a speedy drug review program after a dispute over the approval decision. The agency missed its goal date of April 21 to deliver a decision to Sanofi. The dispute involved acting Center for Drug Evaluation and Research director Tracy Beth Høeg.